<?xml version="1.0" encoding="UTF-8"?>
<p id="Par27">The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund $384m to Novavax for manufacturing Matrix-M adjuvant and NVX-CoV2373 vaccine antigen of COVID-19 vaccine which would boost rapid production of antibodies.</p>
